The melanoma market is predicted to surge during the forecast period (2025–2034) owing to factors, as the increasing incidence of melanoma, the launc ...

JP Morgan reported in their recent outlook piece that "The backdrop for the European consumer is also improving. Real wages ...

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.

GSK plc recently received approval from the U.S. Food and Drug Administration (FDA) for a prefilled syringe version of SHINGRIX, the company’s vaccine for shingles (herpes zoster). The ...

Amid plans to transfer manufacturing for an investigational vaccine to a souped-up plant in Pennsylvania, GSK is parting ways ...

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Sanofi is buying U.K. biotechnology company Vicebio for up to $1.6 billion in a deal that seeks to strengthen the French drugmaker's portfolio of respiratory vaccines and leave pipeline setbacks ...

The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.

Xelix, a leading agentic AI software company in the Accounts Payable (AP) space, today announced a $160 million Series B ...

The Cancer Immunotherapy market, valued at USD 220.94 billion in 2024, is expected to register robust revenue CAGR of 13.6%.

The Global Bladder Cancer Market was valued at USD 4.4 Billion in 2024, and it is expected to reach USD 7.2 Billion by 2035, ...